- Conditions
- Cardiovascular Disease, de Novo Coronary Lesions
- Interventions
- TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,016 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 53
- States / cities
- Scottsdale, Arizona • Bakersfield, California • Rancho Mirage, California + 49 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 934
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Crohn Disease
- Interventions
- Diet
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 35
- States / cities
- Tucson, Arizona • San Francisco, California • Denver, Colorado + 27 more
- Conditions
- Crohn's Disease
- Interventions
- placebo for risankizumab IV, risankizumab SC, risankizumab IV
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 618 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 114
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 89 more
- Conditions
- Acute Leukemia, Chronic Leukemia, Myelodysplasia
- Interventions
- biologic sample preservation procedure
- Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 142
- States / cities
- Mountain View, California • Pismo Beach, California • San Diego, California + 98 more
- Conditions
- Chronic Kidney Disease (CKD)
- Interventions
- Epoetin Hospira Arm, Standard of Care Arm, IV Iron
- Biological · Other · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 432 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 42
- States / cities
- Chula Vista, California • Poway, California • Rancho Bernardo, California + 24 more
- Conditions
- Crohn's Disease
- Interventions
- placebo for risankizumab, risankizumab IV, risankizumab SC
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 931 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 117
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 94 more
- Conditions
- Colorectal Cancer
- Interventions
- Blood Sample Collection
- Other
- Lead sponsor
- Exact Sciences Corporation
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 23,494 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 194
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 160 more
- Conditions
- Primary Systemic (AL) Amyloidosis
- Interventions
- NEOD001, Placebo
- Drug · Other
- Lead sponsor
- Prothena Biosciences Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 32
- States / cities
- Scottsdale, Arizona • Duarte, California • Stanford, California + 26 more
- Conditions
- Osteoarthritis, Avascular Necrosis of Bone of Hip, Post-traumatic; Arthrosis, Congenital Hip Dysplasia
- Interventions
- Vivacit-E Liner
- Device
- Lead sponsor
- Zimmer Biomet
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2028
- U.S. locations
- 5
- States / cities
- Parker, Colorado • Chapel Hill, North Carolina • Charlotte, North Carolina + 2 more
- Conditions
- Mixed Mesodermal (Mullerian) Tumor, Ovarian Carcinosarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage I Ovarian Cancer AJCC v6 and v7, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IA Ovarian Cancer AJCC v6 and v7, Stage IA Uterine Sarcoma AJCC v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IB Ovarian Cancer AJCC v6 and v7, Stage IB Uterine Sarcoma AJCC v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7, Stage IC Ovarian Cancer AJCC v6 and v7, Stage IC Uterine Sarcoma AJCC v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIA Uterine Sarcoma AJCC v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIB Uterine Sarcoma AJCC v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIA Uterine Sarcoma AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIB Uterine Sarcoma AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IIIC Uterine Sarcoma AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7, Stage IVA Uterine Sarcoma AJCC v7, Stage IVB Uterine Sarcoma AJCC v7, Uterine Carcinosarcoma
- Interventions
- Carboplatin, Ifosfamide, Paclitaxel, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- GOG Foundation
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 637 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 532
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 346 more
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- Regorafenib (BAY 73-4506), FOLFIRI, Placebo
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 23
- States / cities
- Denver, Colorado • Miami, Florida • Tampa, Florida + 19 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Etanercept, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 3,080 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 143
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 125 more
- Conditions
- Tuberous Sclerosis Complex
- Interventions
- Ganaxolone, Placebo
- Drug
- Lead sponsor
- Marinus Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 65 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Orange, California + 20 more
- Conditions
- Alopecia Areata
- Interventions
- CTP-543, Placebo
- Drug
- Lead sponsor
- Concert Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 35 more
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Acquired Aplastic Anemia, Sickle Cell Disease
- Interventions
- Donor Search Prognosis Score
- Other
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- Not listed
- Enrollment
- 1,753 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 52
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 40 more
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
- Interventions
- Clinical Observation, Laboratory Biomarker Analysis, Paclitaxel, Paclitaxel Poliglumex, Quality-of-Life Assessment
- Other · Drug · Procedure
- Lead sponsor
- GOG Foundation
- Network
- Eligibility
- Female only
- Enrollment
- 1,157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2022
- U.S. locations
- 315
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 228 more
- Conditions
- Colorectal Cancer
- Interventions
- Capecitabine, Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,886 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 48
- States / cities
- Mobile, Alabama • Alhambra, California • Bakersfield, California + 43 more
- Conditions
- Urinary Incontinence, Overactive Bladder
- Interventions
- Botulinum toxin type A, Placebo
- Biological · Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 27 more
- Conditions
- Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney
- Interventions
- Bardoxolone methyl
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 53 more
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroids
- Interventions
- Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo, Elagolix Placebo
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 155
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 112 more
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Placebo, Cenicriviroc
- Drug
- Lead sponsor
- Tobira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,778 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 204
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 144 more
- Conditions
- Dry Eye Syndromes, Keratoconjunctivitis Sicca
- Interventions
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Drug
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 918 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
- Conditions
- Melanoma
- Interventions
- Elesclomol (STA-4783), Paclitaxel
- Drug
- Lead sponsor
- Synta Pharmaceuticals Corp.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 61
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more
- Conditions
- Sarcoma
- Interventions
- trabectedin
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 32
- States / cities
- Los Angeles, California • Hartford, Connecticut • New Britain, Connecticut + 25 more